Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 sotatercept study in hemodialysis patients with end-stage kidney disease switched from ESA therapy
2012-003788-23Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotatercept in anemia of chronic kidney disease (3 arms), sponsored by Celgene Corporation. Started Sep 2013; status: completed.
02
Drugs
sotatercept
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2012-003788-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003788-23.